Introduction
============

Asthma is one of the most common chronic, non-infectious airway diseases in children, with a global prevalence of 1--18% ([@B13]; [@B47]). As a developing country, with the change of industrialization and lifestyle, the incidence of asthma in Chinese children is rising ([@B20]). Asthma is characterized by chronic airway inflammation, airway hyperresponsiveness and airway remodeling ([@B19]). However, asthma in childhood and adult asthma is significantly different in epidemiology. Respiratory syncytial virus (RSV) is one of the main causes of recurrent asthma in children ([@B27]; [@B54]). Moreover, epidemiological studies have shown that early infection with RSV can increase the risk of asthma in children ([@B4]). Experiments have confirmed that the increased eosinophils can be found in airway of infants and mice after infection with RSV, which is associated with the involvement of viral prion-induced Th2 type cytokines as well as eosinophil chemotactic factors during RSV replication ([@B49]). In addition, RSV infection can also cause damage to the airway surface ([@B61]). At present, research on the role of RSV infection in asthma via proteomics has ever been yet reported.

The prevalence of asthma in children in China is 3.01% ([@B34]). However, the long-term use rate of ICS is only 57.8% ([@B35]). As a traditional medication, herbal compound has become a common alternative treatment for asthma in children in China and other Asian countries ([@B23]; [@B17]). At the molecular level, traditional Chinese medicine formulations are multi-targeted and multi-component. Combinatorial systems biology and omics technology currently provide powerful tools for addressing the complexities and mechanisms of traditional Chinese medicine formulations ([@B60]; [@B7]).

Gubenfangxiao decoction (GBFXD) has been used clinically for decades. It is consisted of traditional Chinese medicine compound Yupingfeng powder (YPF-P) and Ershen Tang (ECD). Previous clinical trials have confirmed the efficacy and safety for long-term prevention of asthma recurrence ([@B59]). Subsequent studies have shown that GBFXD can reduce lung inflammation in OVA-sensitized mice, inhibit the expression of asthma susceptibility genes ORMDL3 and ADAM33, and reduce endoplasmic reticulum stress (ERS) ([@B24]; [@B38]). In this study, as a model of chronic persistant asthma, RSV-OVA-sensitized mice was established. iTRAQ-based proteomics studies and ingenuity pathway analysis (IPA) were performed to reveal the protein features of RSV-OVA-sensitized mice and investigate the underlying mechanisms of GBFXD.

![Effect of GBFXD treatment on airway hyperresponsiveness in ovalbumin-challenged mice and histological examination of lung tissue for airway inflammation (H&E and PAS staining). **(A)** Experimental scheme for the induction of airway inflammation in a mouse model. **(B)** H&E staining showing asthmatic inflammation. PAS staining identified epithelial goblet cells. **(C)** Total inflammation scores in all animal groups. The percentage of PAS-positive cells per bronchiole was calculated. **(D)** Airway responsiveness to aerosolized methacholine was measured with WBP. Mice were placed in the main chamber and nebulized first with PBS and then with increasing doses (3.125--50 mg/mL) of methacholine. Data represent the mean ± SEM of five independent experiments (two-way ANOVA by Tukey's multiple comparisons test; ^∗∗^*p* \< 0.01; ^∗∗∗^*p* \< 0.0001; ^∗∗∗∗^*p* \< 0.0001).](fphar-10-00441-g001){#F1}

Materials and Methods {#s1}
=====================

Animal Experiments and Drug Treatments
--------------------------------------

### GBFXD Preparation

GBFXD, which consists of 11 components ([Table 1](#T1){ref-type="table"}), was purchased from the Jiangsu Province Hospital of Chinese Medicine (Jiangsu, China) and authenticated by Dr. Sheng-Jin Liu of the College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China. The principal components of GBFXD were prepared and identified by high-performance liquid chromatography-ultraviolet in a previous study ([@B38]).

###### 

GBFXD composition.

  Component                                            Part               Weight (g)
  ---------------------------------------------------- ------------------ ------------
  Radix astragali preparata cum melle (Zhi Huang Qi)   Root               15
  *Codonopsis* radix (Dang Shen)                       Root               10
  *Atractylodis macrocephalae* rhizoma (Bai Zhu)       Rhizome            10
  Poria (Fu Ling)                                      Sclerotia          10
  Calcined concha Ostreae (Duan Mu Li)                 Shell              15
  *Periostracum cicadae* (Chan Tui)                    Slough             6
  Citri pericarpium reticulatae (Chen Pi)              Peel               6
  *Saposhnikoviae* radix (Fang Feng)                   Root               3
  Flos Magnoliae (Xin Yi)                              Bud                6
  *Schisandrae Chinensis* fructus (Wu Wei Zi)          Fruit              6
  *Glycyrrhizae* radix et rhizoma (Zhi Gan Cao)        Rhizome and root   3

### Animal Model Establishment

Four-week-old, female, specific-pathogen-free BALB/c mice (16--18 g) were purchased from Suzhou JOINN Laboratories Co., Ltd. (Jiangsu, China). The animals were housed in the experimental animal center of Nanjing University of Chinese Medicine and maintained under a 12 h light/dark cycle at a constant temperature of 22 ± 2°C. Cages, bedding, food, and water were sterilized before use. Mice were sensitized with 20 μg intraperitoneal OVA injections (grade II; Sigma-Aldrich, St. Louis, MO, United States), after which the clinical remission asthmatic (CRA) and chronic persistent asthmatic (CPA) models were established at two different challenge frequencies. The excitation models included 2.5% OVA atomization and RSV in nasal drop form with a titer of 1.0 × 10 TCID~50~/mL ([Figure 1A](#F1){ref-type="fig"}). The mice were randomly divided into six groups as follows, CON-CRA control group, MOD-CRA model group, GBF-CRA (36 g/kg/d) treatment group, CON-CPA control group, MOD-CPA model group, and GBF-CPA (36 g/kg/d) treatment group. Prior to the experiments, there were no significant differences among the groups in terms of animal weight. All experimental procedures were performed in accordance with the National Institutes of Health Guidelines for Laboratory Animals and approved by the Animal Ethics Committee of Nanjing University of Chinese Medicine \[no. SYXK (Su) 2014--0001\].

Proteomics
----------

### Protein Extraction and Digestion

Lungs were excised, immediately frozen at −80°C, and ground in liquid N~2~. Cold RIPA extraction buffer (Beyotime, Haimen, China) was added to the pulverized tissue and then the mixture was sonicated. Next, 1 mM phenylmethanesulfonyl fluoride (Beyotime), 2 mM ethylenediaminetetraacetic acid, 10 mM dithiothreitol, and protease inhibitor cocktails (Roche, Basel, Switzerland) were added, after which the mixture was centrifuged at 4°C and 30,000 × *g* for 15 min. The supernatant was collected and added to five volumes of cold acetone containing 10% (v/v) trichloroacetic acid, thoroughly mixed, and incubated at −20°C overnight. The mixture was centrifuged again at 4°C and 30,000 × *g* and the supernatant was discarded. The precipitate was then washed three times with chilled acetone, dissolved in RIPA buffer, and air-dried. Proteins were quantified with a BCA kit (Thermo Fisher Scientific, Waltham, MA, United States), after which 300 μg of total protein was mixed with sequencing-grade trypsin (Promega, Madison, WI, United States) at an enzyme-to-protein ratio of 1:50 and incubated at 37°C for 16 h. Peptides obtained from the digestion were dried by vacuum centrifugation.

### iTRAQ Labeling and High-pH Reverse-Phase (RP) Fractionation

Peptides were processed using 4-plex iTRAQ reagent (AB Sciex, Framingham, MA, United States) according to manufacturer's instructions. Control samples were labeled with 116 iTRAQ tags, model samples were labeled with 115 iTRAQ tags, GBFXD samples were labeled with 114 iTRAQ tags, and the mixtures were labeled with 117 iTRAQ tags. High pH RP fractionation was then performed with the U3000 HPLC chromatography system (Thermo Fisher Scientific). The iTRAQ-labeled peptide mixtures were reconstituted with 100 μL of high pH RP buffer A (98% H~2~O, 2% acetonitrile; pH 10.0) and loaded onto a C18 column with a particle size of 1.7 μm (2.1 mm × 100 mm; Waters Corporation, Milford, MA, United States). The column was eluted with the following gradient program, 3--18% buffer B (2% H~2~O, 98% acetonitrile; pH 10.0) for 30 min; 18--32% B for 15 min; 32--98% B for 6 min; and holding at 98% B for 15 min. The flow rate was 0.2 mL/min and elution was monitored by measuring the absorbance at 214 nm.

### Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Analysis

Peptides were re-dissolved in buffer A (2% acetonitrile, 0.1% formate) and centrifuged at 4°C and 20,000 × *g* for 10 min. The final peptide concentration of each fraction was ∼0.2 μg/μL. The peptides (10 μL) were then loaded onto a 2-cm C18 trap column using the Nano LC System autosampler (Thermo Fisher Scientific) and eluted onto a 15-cm analytical C18 column with an inner diameter of 75 μm using a 3--55% buffer B (84% acetonitrile, 0.1% formate) gradient. The elution process ran for 112 min at a flow rate of 300 nL/min. The peptides were ionized via nano-electrospray ionization at a voltage of 2.2 kV. Data-dependent MS/MS was performed using an LTQ-Orbitrap XL mass spectrometer (Thermo Fisher Scientific). Using the MS1 full scan at a resolution of 60,000, the five most abundant precursor ions surpassing the 5,000 count threshold were selected for MS/MS analysis at a dynamic exclusion duration of 60 s. Normalized collision energy for high-energy collision dissociation (HCD) was set to 40.0. Finally, the ion fragments were detected in the Orbitrap at a resolution of 7,500 m/z scan ranges were 350--1800 and 100--1800 Da for the MS1 and the MS2 scans, respectively.

### Protein Identification and Quantification

Raw MS data were converted into.MGF files using Proteome Discoverer v.1.4 (Thermo Fisher Scientific). Proteins were identified with the SEQUEST search engine and considered differentially expressed when their fold changes were \> 1.5 or \<0.66 and *p* \< 0.05. Parameters required for qualification are listed in [Table 2](#T2){ref-type="table"}.

###### 

Parameters required for qualification.

  Parameter
  -----------------------------------------------------------
  Enzyme: trypsin
  Miss cleavage: 2
  MS/MS tolerance ppm: 10
  Fixed modification: carbamidomethylation (C)
  Variable modification: oxidation (M) and deamidation (NQ)
  Unique peptide: 2
  Peptide FDR: 0.01

### Bioinformatic Analysis of Differentially Expressed Proteins (DEPs)

Protein-encoding genes were functionally categorized according to biological process, molecular function, and cellular components by the PANTHER gene classification system. Proteomic data were analyzed by Ingenuity^®^ Pathways Analysis (IPA; Qiagen, Hilden, Germany) to elucidate the hidden biological significance of the experimental data. Biological information obtained from data analysis is presented as biological function/disease, canonical pathways, networks, and upstream regulators.

Histopathology
--------------

Lung tissues were infused with 4% paraformaldehyde, embedded in paraffin, and processed for histology. Paraffin-embedded samples were sectioned (5-mm thick) and stained with hematoxylin and eosin (H&E) to examine the extent of peribronchial inflammation. Glandular hyperplasia was analyzed in randomly selected samples using the periodic acid Schiff (PAS) staining method.

Airway Hyperresponsiveness (AHR) Testing
----------------------------------------

BABL/c mice in their natural state were placed in Whole Body Plethysmography(WBP) and allowed to stabilize for 3 min to adapt to the environment. Basic physiological respiratory parameters were measured for 3 min, after which normal saline was added to the inhalation tubes in the boxes. Diluted methacholine (300 μL) was then injected into the boxes at a concentration of 0, 3.125, 6.25, 12.5, and 25 g/L. The mist generation rate was adjusted to 50%. For every minute of nebulization and inhalation, Enhanced pause (Penh) values were calculated using the software of the associated computer interface; the average Penh value at each challenge dose was calculated 3 min after inhalation.

Validation
----------

Total RNA from the lung samples was isolated using TRIzol reagent (Takara Bio, Kusatsu, Japan) according to manufacturer's instructions. Reverse transcription master mix (G490) and EvaGreen qPCR master mix (MasterMix-ER) were purchased from Applied Biological Materials Inc. (Richmond, BC, Canada). *ARG1, MRC1, Retnla, CHIL3*, *TNF*, and *IFNG* mRNA levels were determined by quantitative reverse transcription (qRT)-PCR using GAPDH as a reference gene ([Table 3](#T3){ref-type="table"}). Expression levels of ARG1, CHIA, and Retnla (Abcam, Cambridge, United Kingdom) in lung tissue were also measured by western blotting using β-actin as loading control. Protein samples from the lungs were fractionated via SDS-PAGE. Three independent experiments were performed.

###### 

Primer sequences.

  Gene       Forward primer                Reverse primer              Expected product size (bp)
  ---------- ----------------------------- --------------------------- ----------------------------
  *Arg1*     CCGAGGATGGAGAGCAGCTAGG        CCTGAGAGTCTGTGCCAATGAGC     150
  *Retnla*   ACTTCTTGCCAATCCAGCTAACTATCC   GCAGTGGTCCAGTCAACGAGTAAG    204
  *CHIL3*    CAGTGTTCTGGTGAAGGAAATG        ACCCAGACTTGATTACGTCAAT      119
  *Mrc1*     GTCTGAGTGTACGCAGTGGTTGG       TCTGATGATGGACTTCCTGGTAGCC   85
  *IFNG*     GCGTCATTGAATCACACCTG          TGAGCTCATTGAATGCTTGG        129
  *TNF*      GCGACGTGGAACTGGCAGAAG         CATCGGCTGGCACCACTAGTTG      327
  *GAPDH*    CGTGTTCCTACCCCCAATGT          TGTCATACTTGGCAGGTTT         104

Data Analysis
-------------

Data are expressed as the mean ± standard error of the mean (SEM). All statistical analyses were performed using GraphPad Prism 6.0 (GraphPad Software Inc., San Diego, CA, United States). Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Dunnett's *post hoc* test to determine the statistical significance. Differences were considered significant when *p* \< 0.05.

Results
=======

GBFXD Alleviates Airway Inflammation and AHR Caused by Persistent Challenge
---------------------------------------------------------------------------

We improved the previous method ([@B38]) and established a CPA model that more closely simulates chronic persistent asthmatic characteristics than the one previously tested. H&E staining, PAS staining, and AHR of the two models tested were compared. In both models, the mice developed typical inflammatory changes including bronchial congestion and inflammatory cell infiltration. Mucus expression in the airways was evaluated by quantifying and comparing PAS-positive cells between the two models; the CPA model presented with more prominent goblet cell hyperplasia and mucus overproduction. After GBFXD treatment, however, the average number of PAS-stained goblet cells was greatly reduced ([Figure 1B,C](#F1){ref-type="fig"}). Asthma is an airway obstruction often accompanied by varying degrees of AHR. As the Penh metric can reflect airway responsiveness and Penh values are accepted AHR indicators, we calculated Penh values after induction with a methacholine concentration gradient. We found higher AHR in the CPA model than in the CRA model, with GBFXD showing significantly reduced AHR ([Figure 1D](#F1){ref-type="fig"}).

Proteomic Expression Patterns
-----------------------------

To compare the pathological and pulmonary function results, we selected the CPA model for further proteomic experiments. A total of 1,956 proteins were identified by iTRAQ with a \< 1% false discovery rate (FDR) after analyzing three biological replicates of mouse lung tissue. Proteins with significantly altered expression levels at a fold change cut-off of \> 1.5 relative to the model group were considered DEPs (*p* \< 0.05). We found 71 DEPs in the model group compared with control; 17 proteins were downregulated while 54 proteins were upregulated ([Figure 2A](#F2){ref-type="fig"} and [Table 4](#T4){ref-type="table"}). Moreover, a total of 68 proteins were differentially expressed after GBFXD treatment compared with that of the model group; 47 proteins were upregulated and 20 were downregulated ([Figure 2B](#F2){ref-type="fig"} and [Table 5](#T5){ref-type="table"}). EIF4B, HBA1/HBA2, Hist1h1e, HLA-A, and LYVE1 were repressed in the model group but were found upregulated after GBFXD treatment. In contrast, ANXA8/ANXA8L1, APOA, ARG1, CHIA, CYP1A1, FTL, H2AFZ, PLPP3, Retnla, S100A4, and TSN were induced in the model group but downregulated in response to GBFXD treatment ([Figure 2C](#F2){ref-type="fig"}). Furthermore, DEPs were classified using the PANTHER gene classification systems and the enriched gene ontology (GO) terms were found enriched compared with the control group, hydrolase activity (GO:0016787), protein binding (GO:0005515), metabolic process (GO:0008152), and response to stimuli (GO:0050896). DEPs between the GBFXD and model groups were mainly involved in metabolic processes (GO:0008152), cellular processes (GO:0009987), cellular component organization or biogenesis (GO:0071840), intracellular processes (GO:0005622), and protein binding (GO:0005515; [Figure 2D--I](#F2){ref-type="fig"}).

![Protein expression profiles. **(A,B)** Heatmap of the expression levels of differentially expressed proteins (DEPs) compared with those of the model group quantified by iTRAQ-based stable isotope tagging. **(C)** Venn diagrams showing the distribution of shared DEPs. Blue represents upregulated proteins in the model group (up in MOD), green represents downregulated proteins in the model group (down in MOD), pink represents upregulated proteins in the GBFXD group (up in GBF), and yellow represents downregulated proteins in the GBFXD group (down in GBF). Overlapping sections indicate the number of common proteins across different groups. GO, gene ontology enrichment analysis. GO analysis of DEPs after modeling; **(D)** biological process, **(E)** cellular component, and **(F)** molecular function. GO analysis of DEPs after GBFXD treatment; **(G)** biological process, **(H)** cellular component, and **(I)** molecular function.](fphar-10-00441-g002){#F2}

###### 

Differentially expressed proteins (DEPs) in the CON group compared with the MOD group.

  Expression fold change   ID           Symbol                        Entrez gene name
  ------------------------ ------------ ----------------------------- -------------------------------------------------------------------
  −4.011                   O88990       Actn3                         Actinin alpha 3
  −4.834                   P03958       ADA                           Adenosine deaminase
  −1.877                   O35640       ANXA8/ANXA8L1                 Annexin A8 like 1
  −1.563                   Q810I7       APOA4                         Apolipoprotein A4
  −3.331                   Q61176       ARG1                          Arginase 1
  −1.622                   Q69Z96       ATP13A1                       ATPase 13A1
  −2.623                   Q8R429       ATP2A1                        ATPase sarcoplasmic/endoplasmic reticulum Ca^2+^ transporting 1
  1.675                    B1ASE2       ATP5H                         ATP synthase, H+ transporting, mitochondrial Fo complex subunit D
  −6.174                   Q61114       BPIFB1                        BPI fold containing family B member 1
  −1.556                   Q3TNN6       CAPG                          Capping actin protein, gelsolin like
  −2.274                   Q61362       CHI3L1                        Chitinase 3 like 1
  −2.707                   Q91XA9       CHIA                          Chitinase, acidic
  −6.08                    O35744       Chil3/Chil4                   Chitinase-like 3
  −1.812                   P07310       CKM                           Creatine kinase, M-type
  −4.014                   Q9D7Z6       CLCA1                         Chloride channel accessory 1
  1.825                    P02463       COL4A1                        Collagen type IV alpha 1 chain
  −1.871                   D3Z315       COPE                          Coatomer protein complex subunit epsilon
  −1.82                    P00184       CYP1A1                        Cytochrome P450 family 1 subfamily A member 1
  1.636                    Q922K6       EIF4B                         Eukaryotic translation initiation factor 4B
  −2.16                    Q3THE6       FTL                           Ferritin light chain
  −1.552                   Q3UA95       H2AFZ                         H2A histone family member Z
  1.609                    P01942       HBA1/HBA2                     Hemoglobin subunit alpha 2
  1.753                    A8DUV1       HBA1/HBA2                     Hemoglobin subunit alpha 2
  2.24                     P43274       Hist1h1e                      Histone cluster 1, H1e
  1.528                    P01900       HLA-A                         Major histocompatibility complex, class I, A
  −1.82                    A0A068BD71   HLA-DQA1                      Major histocompatibility complex, class II, DQ alpha 1
  −1.809                   P01921       HLA-DQB1                      Major histocompatibility complex, class II, DQ beta 1
  −1.754                   P01915       HLA-DRB5                      Major histocompatibility complex, class II, DR beta 5
  −1.594                   Q861Q5       HM13                          Histocompatibility minor 13
  −1.791                   Q66K04       Igh                           Immunoglobulin heavy chain complex
  −1.885                   P01868       IGHG1                         Immunoglobulin heavy constant gamma 1 (G1m marker)
  −1.905                   P01872       IGHM                          Immunoglobulin heavy constant mu
  −1.94                    A0A075B5V1   Ighv1-31                      Immunoglobulin heavy variable 1--31
  −2.789                   A0A075B5J9   Igkv17-127                    Immunoglobulin kappa variable 17--127
  −2.286                   A0A0B4J1J0   Igkv4-50                      Immunoglobulin kappa variable 4--50
  −5.083                   Q9U410       Igkv4-55                      Immunoglobulin kappa variable 4--55
  −3.655                   A0A0B4J1J2   Igkv5-43                      Immunoglobulin kappa chain variable 5--43
  −7.651                   P01592       JCHAIN                        Joining chain of multimeric IgA and IgM
  1.668                    Q8BHC0       LYVE1                         Lymphatic vessel endothelial hyaluronan receptor 1
  −1.705                   Q6ZQJ2       METAP1                        Methionyl aminopeptidase 1
  −1.568                   Q61830       MRC1                          Mannose receptor C-type 1
  −2.894                   P97457       MYLPF                         Myosin light chain, phosphorylatable, fast skeletal muscle
  1.555                    Q3TF41       NAP1L1                        Nucleosome assembly protein 1 like 1
  1.534                    Q7TMG7       NPR3                          Natriuretic peptide receptor 3
  −2.226                   Q62422       OSTF1                         Osteoclast stimulating factor 1
  −1.722                   P08003       PDIA4                         Protein disulfide isomerase family A member 4
  1.556                    D3Z375       PEA15                         Phosphoprotein enriched in astrocytes 15
  −1.885                   Q61753       PHGDH                         Phosphoglycerate dehydrogenase
  −1.921                   O35405       PLD3                          Phospholipase D family member 3
  −1.741                   Q99JY8       PLPP3                         Phospholipid phosphatase 3
  1.649                    Q6PD03       PPP2R5A                       Protein phosphatase 2 regulatory subunit B'alpha
  −1.637                   Q8C6Q7       PTPRC                         Protein tyrosine phosphatase, receptor type C
  2.09                     Q99LE7       PXN                           Paxillin
  1.673                    Q9Z0J1       RECK                          Reversion inducing cysteine rich protein with kazal motifs
  −5.949                   Q9JM62       REEP6                         Receptor accessory protein 6
  −2.315                   Q9EP95       Retnla                        Resistin-like alpha
  −2.726                   P07091       S100A4                        S100 calcium binding protein A4
  −3.757                   Q6ZPE2       SBF1                          SET binding factor 1
  −2.48                    D6RFV4       SEC11C                        SEC11 homolog C, signal peptidase complex subunit
  −2.004                   Q3TT70       SEL1L                         SEL1L ERAD E3 ligase adaptor subunit
  1.583                    P07759       SERPINA3                      Serpin family A member 3
  −2.036                   Q3U0Y1       Serpina3g (includes others)   Serine (or cysteine) peptidase inhibitor, clade A, member 3G
  −2.852                   G3X9V8       SERPINB4                      Serpin family B member 4
  −5.387                   P97298       SERPINF1                      Serpin family F member 1
  −2.29                    Q08189       TGM3                          Transglutaminase 3
  −4.72                    A2AQJ7       TMEM87A                       Transmembrane protein 87A
  1.547                    Q5SVT2       TRIM16                        Tripartite motif containing 16
  −1.52                    Q62348       TSN                           Translin
  1.565                    Q9CQU0       TXNDC12                       Thioredoxin domain containing 12
  −1.979                   E9PXX7       TXNDC5                        Thioredoxin domain containing 5
  −1.803                   Q0VGU5       VKORC1L1                      Vitamin K epoxide reductase complex subunit 1 like 1

###### 

DEPs in the GBF group compared with the MOD group.

  Expression fold change   ID       Symbol                    Entrez gene name
  ------------------------ -------- ------------------------- ----------------------------------------------------------------------------
  −1.548                   O89054   ACTB                      Actin beta
  1.871                    Q9JI91   ACTN2                     Actinin alpha 2
  1.698                    Q9R0Y5   AK1                       Adenylate kinase 1
  −1.711                   O35640   ANXA8/ANX A8L1            Annexin A8 like 1
  −1.784                   Q00623   APOA1                     Apolipoprotein A1
  −1.642                   Q810I7   APOA4                     Apolipoprotein A4
  −1.633                   Q61176   ARG1                      Arginase 1
  1.554                    Q3TJD4   ATP5F1                    ATP synthase, H+ transporting, mitochondrial Fo complex subunit B1
  −1.99                    O54962   BANF1                     Barrier to autointegration factor 1
  2.894                    P16015   CA3                       Carbonic anhydrase 3
  −1.533                   Q91XA9   CHIA                      Chitinase, acidic
  1.626                    P07310   CKM                       Creatine kinase, M-type
  1.76                     P23927   CRYAB                     Crystallin alpha B
  −2.023                   P00184   CYP1A1                    Cytochrome P450 family 1 subfamily A member 1
  −1.781                   Q9R126   Ear7                      Eosinophil-associated, ribonuclease A family, member 7
  1.613                    Q922K6   EIF4B                     Eukaryotic translation initiation factor 4B
  3.173                    P04117   FABP4                     Fatty acid binding protein 4
  −1.7                     G3X9U9   FIS1                      Fission, mitochondrial 1
  −1.743                   Q3THE6   FTL                       Ferritin light chain
  1.504                    Q3UDC0   GBP2                      Guanylate binding protein 2
  1.742                    E9QAZ2   Gm10020                   Ribosomal protein L15 pseudogene
  1.59                     D3YVC6   Gm21596/Hmgb1             High mobility group box 1
  1.655                    P05201   GOT1                      Glutamic-oxaloacetic transaminase 1
  1.758                    E0CXN5   GPD1                      Glycerol-3-phosphate dehydrogenase 1
  −1.56                    Q3UTB8   GRPEL1                    GrpE like 1, mitochondrial
  −1.636                   Q3UA95   H2AFZ                     H2A histone family member Z
  1.792                    Q61425   HADH                      Hydroxyacyl-CoA dehydrogenase
  1.727                    A8DUV1   HBA1/HBA2                 Hemoglobin subunit alpha 2
  2.253                    P43274   Hist1h1e                  Histone cluster 1, H1e
  1.592                    P01900   HLA-A                     Major histocompatibility complex, class I, A
  1.676                    Q9JHU9   ISYNA1                    Inositol-3-phosphate synthase 1
  2.221                    Q8BHC0   LYVE1                     Lymphatic vessel endothelial hyaluronan receptor 1
  1.58                     F6TBV1   MAGT1                     Magnesium transporter 1
  1.63                     E0CYU5   MAT2B                     Methionine adenosyltransferase 2B
  1.541                    Q9D1H9   MFAP4                     Microfibrillar associated protein 4
  2.021                    P34884   MIF                       Macrophage migration inhibitory factor (glycosylation-inhibiting factor)
  4.167                    E9QK82   MPZ                       Myelin protein zero
  2.178                    Q3TF37   MYBPC3                    Myosin binding protein C, cardiac
  1.517                    Q02566   MYH6                      Myosin heavy chain 6
  1.782                    A2A6Q8   MYL4                      Myosin light chain 4
  1.661                    Q9QVP4   MYL7                      Myosin light chain 7
  1.609                    P97457   MYLPF                     Myosin light chain, phosphorylatable, fast skeletal muscle
  1.591                    Q14BI5   MYOM2                     Myomesin 2
  1.825                    O35683   NDUFA1                    NADH:ubiquinone oxidoreductase subunit A1
  1.509                    Q9DC69   NDUFA9                    NADH:ubiquinone oxidoreductase subunit A9
  1.545                    Q9DC70   NDUFS7                    NADH:ubiquinone oxidoreductase core subunit S7
  1.829                    Q3TF69   PCBP2                     Poly(rC) binding protein 2
  1.631                    P47857   PFKM                      Phosphofructokinase, muscle
  1.634                    O35129   PHB2                      Prohibitin 2
  1.513                    Q3TD51   PICALM                    Phosphatidylinositol binding clathrin assembly protein
  −1.698                   Q99JY8   PLPP3                     Phospholipid phosphatase 3
  1.53                     Q9WUB3   PYGM                      Glycogen phosphorylase, muscle associated
  −1.572                   Q9EP95   Retnla                    Resistin like alpha
  1.523                    Q9D1R9   Rpl34 (includes others)   Ribosomal protein L34
  1.88                     Q9JJI8   RPL38                     Ribosomal protein L38
  1.666                    P62267   RPS23                     Ribosomal protein S23
  −1.779                   Q9JL08   S100A1                    S100 calcium binding protein A1
  −1.59                    P07091   S100A4                    S100 calcium binding protein A4
  1.534                    Q8BGH2   SAMM50                    SAMM50 sorting and assembly machinery component
  1.701                    P36536   SAR1A                     Secretion associated Ras related GTPase 1A
  −1.541                   A2BE92   SET                       SET nuclear proto-oncogene
  1.804                    Q7TQ48   SRL                       Sarcalumenin
  1.924                    K3W4R6   TNNT2                     Troponin T2, cardiac type
  −1.6                     Q62348   TSN                       Translin
  1.595                    Q9CQM5   TXNDC17                   Thioredoxin domain containing 17
  1.93                     Q78IK2   USMG5                     Up-regulated during skeletal muscle growth 5 homolog (mouse)
  −1.707                   P68510   YWHAH                     Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta

Analysis of Proteomic Data via IPA
----------------------------------

### Proteomic Analysis of the Model

Proteomic data were analyzed via IPA, in which proteins are analyzed as a network using canonical pathways, disease networks, and predicted upstream regulators. Bioinformatic analysis showed that the model was involved in 165 pathways and 80 biological functions ([Figure 3](#F3){ref-type="fig"}). Functional enrichments in inflammatory response, respiratory diseases, and inflammatory disease suggest that this model exhibits significant pulmonary inflammation. The high degree of enrichment in organismal injury and abnormalities, connective tissue disorders, and tissue morphology also suggests substantial changes in histomorphology. Humoral immune response and immune cell trafficking were also highly involved. The top 20 enriched disease and function terms are shown in [Figure 3A](#F3){ref-type="fig"}. Canonical pathway analysis of the data revealed that our established model significantly activated multiple pathways in the mouse immune system; these included B-cell development, calcium-induced lymphocyte apoptosis, antigen presentation, iCOS-iCOSL signaling in T-helper cells, dendritic cell maturation, PKCθ signaling in T-lymphocytes, and Th1 and Th2 activation pathways. We also found that the DEPs were associated with 30 metabolic pathways. Upstream regulator predictions suggested that six inflammatory cytokines were upregulated and one downregulated (*Z*-Score \> 1 or \<−1); among the upregulated cytokines, the classical Th2 cytokines interleukin (IL)-4 and IL-5 drive M2 macrophage polarization in asthma pathogenesis ([Table 6](#T6){ref-type="table"}). Moreover, ARG1, MRC1, Chil3/Chil4, CHIA, and Retnla are typical cytokines secreted by M2 macrophages typical M2 cytokines that were found among the DEPs. In addition, GSF1, GSF2, cyclooxygenase, and prostaglandin E2 were significantly predicted upstream. These findings suggest that macrophages play an important role in this asthma model ([Table 6](#T6){ref-type="table"}). We further edited and expanded the functional network according to the molecular relationship most strongly correlated with the DEPs. The results showed that the DEPs constitute a reliable network and participate in inflammation and immune cell trafficking. The expression of the M2-type macrophage factors ARG1, MRC1, Chil3/Chil4, and Retnla is related to serum amyloid A (SAA) and cyclooxygenase. HBA1/HBA2 is a common biochemical indicator in the network. Therefore, there is abnormal blood oxygen saturation in the reaction state ([Figure 3F](#F3){ref-type="fig"}).

![Bioinformatic analysis of DEPs between the control and model groups using Ingenuity Pathway Analysis (IPA) and *z*-score algorithms. **(A)** Biological function enrichment. **(B)** Canonical pathways enrichment (*p*-values for all functions and pathways presented are \< 0.05). **(C--E)** Upstream regulatory factors predicted based on DEPs. **(F)** Relationships between DEPs and proteins predicted to be involved in interactions, as well as relevant signaling pathways, are presented. Statistical predictions of the networks were based on the Ingenuity Knowledge base. Red nodes represent upregulated proteins and green nodes represent downregulated proteins.](fphar-10-00441-g003){#F3}

###### 

Upstream analysis of CON vs. the MOD group.

  Upstream regulator   Predicted activation state   Activation *z*-score   *p*-value of overlap   Target molecules in dataset
  -------------------- ---------------------------- ---------------------- ---------------------- -------------------------------------------------------------------------------------------------------------------------------
  Cyclooxygenase       Inhibited                    −2                     2.86E-07               ARG1, Chil3/Chil4, MRC1, Retnla
  IL4                  Inhibited                    −2.412                 1.63E-06               ARG1, ATP2A1, CAPG, Chil3/Chil4, Hist1h1e, IGHG1, JCHAIN, METAP1, MRC1, NAP1L1, Retnla, Serpina3g (includes others), SERPINB4
  IL21                 Inhibited                    −2.236                 1.88E-04               ARG1, HLA-DRB5, IGHG1, PTPRC, Serpina3g (includes others)
  IL5                  Inhibited                    −2.376                 2.05E-04               IGHG1, IGHM, JCHAIN, PTPRC, S100A4, Serpina3g (includes others)
  Prostaglandin E2     Inhibited                    −2.191                 2.23E-03               ARG1, Chil3/Chil4, IGHG1, MRC1, Retnla
  CSF1                 Inhibited                    −2                     2.54E-03               ARG1, MRC1, PTPRC, Retnla
  CSF2                 Inhibited                    −2.219                 1.22E-02               ADA, ARG1, HLA-DQB1, MRC1, PHGDH

### Proteomic Analysis Revealed the Therapeutic Effects of GBFXD

Ingenuity pathway analysis correlation analysis was performed to compare the GBFXD treatment and model groups and a total of 159 pathways were found to be involved. Pathways with significant regulation included actin cytoskeleton signaling, rho regulation of actin-based motility, ILK signaling, and sirtuin signaling. In addition, highly enriched pathways included mitochondrial dysfunction and oxidative phosphorylation. DEPs were found associated with 76 biological programs, 6 metabolic pathways, the immune program, and morphologically related programs; lipid and carbohydrate metabolism were the most enriched. Networks constructed with DEPs suggested that GBFXD treatment may have increased mitochondrial respiratory function and oxidative phosphorylation ([Figure 4](#F4){ref-type="fig"}). Furthermore, we compared the highest scoring internetworks predicted by the two protein groups. Seven points were coincident (ARG1, cyclooxygenase, ERK1/2, HBA1/HBA2, hemoglobin, Retnla, and SAA; [Figure 4](#F4){ref-type="fig"}); among them, ARG1, Retnla, and HBA1/HBA2 were common DEPs to both groups. Network analysis suggested that GBFXD regulates mitochondrial energy metabolism and corrects M2 factor expression. Moreover, it was predicted that IFNG is significantly activated after GBFXD treatment, which supports our previous experimental findings. Upstream regulatory factor prediction also suggested that GBFXD significantly inhibits RICTOR. Taken together, the two significant upstream predictions indicate that GBFXD inhibits M2 macrophages in our model.

![Bioinformatic analysis of DEPs in the lung after GBFXD treatment. **(A)** Biological function enrichment. **(B)** The most enriched pathways as a summary of DEPs between the GBFXD and model groups. **(C)** Regulatory effects resulting from integrating target molecules, upstream factors, and downstream biological functions. **(D)** The most credible interaction networks. **(E)** IPA of mitochondrial function and the oxidative phosphorylation pathway.](fphar-10-00441-g004){#F4}

### Validation

We further performed western blot analysis and found that expression levels of ARG1, CHIA, and Retnla in lung tissue were significantly decreased in the GBFXD group ([Figure 5](#F5){ref-type="fig"}, [Supplementary Data Sheet S1](#SM1){ref-type="supplementary-material"}). This result is in agreement with the protein levels measured by iTRAQ analysis and the changing trends in transcription indicated by qRT-PCR. Therefore, our proteomic analysis output was deemed reliable.

![Validation of differentially expressed candidate proteins identified using proteomics. **(A)** qRT-PCR of six selected genes presented relative to control samples and normalized against GAPDH in each sample. **(B)** Western blot analysis shows decreased ARG1, Retnla, and CHIA levels in the GBFXD group (B). Values represent the means ± SE of three independent experiments with ≥3 replicates per experiment. ^∗∗^*p* \< 0.01; ^∗∗∗^*p* \< 0.0001; ^∗∗∗∗^*p* \< 0.0001.](fphar-10-00441-g005){#F5}

Discussion
==========

Asthma is the most common chronic airway inflammation disorder whose incidence continues to increase worldwide. The pathophysiological features of asthma include continuous chronic airway inflammation, AHR, and airway remodeling. Moreover, there are dramatic epidemiological differences between childhood and adult asthma. As a first-line treatment for asthma, ICS is not well tolerated in children. Moreover, it may be difficult to diagnose asthma in certain children under the age of five ([@B46]; [@B31]; [@B3]; [@B14]). As an alternative to ICS, several Asian countries employ GBFXD against asthma. Previous studies have shown that GBFXD reduces pulmonary inflammation during clinical remission in asthmatic mice ([@B24]; [@B38]) however, the mechanism remains unknown. Therefore, to understand the therapeutic role of GBFXD, we established a clinically consistent chronic asthmatic model and performed proteomic analysis. The study considerated the epidemiological characteristics of asthma in children; this subpopulation often presents with persistent allergen exposure inevitably ([@B51]). Therefore, we increased the frequency of OVA challenges compared with that of our previous model. We compared both models and found that mice in the continuous OVA-induced model exhibit remarkable pathological features that were corroborated by lung function tests.

Alveolar macrophages, airway surface mucus, microorganisms, and airway epithelium constitute the first line of airway defense ([@B25]). Macrophages can be adaptively polarized according to the metabolic characteristics of the tissue and immune environments. Macrophage polarization is categorized as the classical M1 type and the alternative M2 type. M1 polarization is pro-inflammatory and is initiated by adaptive immunity, whereas M2 polarization is anti-inflammatory and is critical for tissue damage and recovery during the late phases of infection ([@B55]; [@B22]). M2 polarization mediates airway remodeling, matrix deposition, and other pathophysiological mechanisms in asthma ([@B56]). Th2 inflammatory factors are required to polarize macrophages toward the M2 phenotype ([@B12]). As OVA is often used to trigger Th2-type immune responses, the combination of OVA and RSV can aggravate Th2-type responses. Furthermore, excessive M2 macrophages are activated in lung tissue after RSV infection ([@B29]; [@B43]). Therefore, the increased M2 macrophage polarization exhibited by our model is credible.

Clinical studies have found that CD206^+^ macrophage is highly expressed in the trachea and bronchoalveolar lavage fluid in asthmatic patients. The degree of its expression is correlated with biological sex, asthma severity, and lung function. However, CD206^+^ macrophage may be insensitive to ICS treatment ([@B41], [@B42]; [@B10]). Markers of alternatively activated macrophages include MRC1, ARG1, Retnla, and Chil3 and these are upregulated in the lungs. Herein, proteomic analysis indicated the presence of M2 macrophage markers, MRC1, ARG1, Retnla, Chil3, and CHIA in asthmatic. GBFXD treatment inhibited these factors ([Supplementary Figure S1A](#SM1){ref-type="supplementary-material"}). The inhibitory effect on M2 macrophages by GBFXD may result from its therapeutic effect in attenuating airway remodeling and ARH, which interact with each other and constitute the hidden pathogen inducing susceptibility to asthma. Therefore, GBFXD may represent an alternative therapeutic agent against asthma.

The upstream predictive function of our experiment indicated that IL-4/IL-5/IL-13 are significantly activated in this model. Arg1 is induced by IL-4/IL-13 in macrophages and counterbalances inflammatory signals. [L]{.smallcaps}-arginine metabolism in macrophages is a defining feature of alternative versus classical macrophage activation ([@B11]). Moreover, chitinase-like protein is elevated in serum and mainly in alveolar cells and macrophages of the lungs of asthmatic patients ([@B8]). *ARG1* and *CHIL3* are well-recognized susceptibility genes closely associated with childhood asthma that increase AHR and weaken lung function; additionally, the polymorphic and epigenetic states of *ARG1* are associated with childhood asthma progression ([@B32]; [@B45]; [@B50]; [@B9]). Retnla (resistin-like molecule-α), also known as FIZZ 1 (found in inflammatory zone 1), is also highly induced in allergic lung inflammation and bleomycin-induced lung fibrosis ([@B21]; [@B36]). Furthermore, macrophages can strongly express Retnla in chronic type 2 inflammation ([@B44]). In agreement, our proteomic analysis identified changes in these proteins that led to clinical outcomes. At the same time, lung function and pathology results also support these conclusions. Therefore, we believe that our model would be valuable in the study of chronic persistent asthma in children.

Mitochondria are the energy centers of cellular activity. They also maintain cellular ion homeostasis and lipid metabolism. Clinical studies have detected dysfunction and structural changes in the mitochondria of airway epithelial cells of asthmatic patients. Similar changes observed in asthmatic animal models indicated that abnormal oxidative stress, mitochondrial membrane potential, and energy metabolism occur ([@B39]; [@B1]; [@B63]; [@B15]; [@B18]; [@B52]). Th1/Th2 imbalance also adversely affects mitochondrial function ([@B5]; [@B48]). Furthermore, arginine and chitinase metabolism affect mitochondrial oxidative stress ([@B62]; [@B6]; [@B57]). In the present study, proteomic analysis showed that after GBFXD treatment, NDUFA1, NDUFA9, NDUFS7, ATP5F1, and HADH were upregulated while FIS1 was downregulated. Pathway and network analyses also suggested that GBFXD increases ATP synthesis and that mitochondrial complex 1 interacts with mitigating M2 macrophage markers ([Supplementary Table S1](#SM2){ref-type="supplementary-material"} and [Supplementary Figure S1B](#SM1){ref-type="supplementary-material"}).

Conclusion
==========

Treatment with GBFXD can improve Th1/Th2 balance, inhibit alternatively activated macrophages, and reduce AHR, mucus secretion, and airway remodeling. We believe that GBFXD shows efficacy due to its mechanism of action, specifically the improvement in macrophage polarization and restoration of mitochondrial function.
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###### 

Effect of GBFXD on expression of M2 and mitochondrial complex 1 marker in macrophages in mouse models. **(A)** Lung tissue was fixed and sections were processed for Immunofluorescence detection of M2 macrophage (CD206+f4/80+). **(B)** After macrophage collected from Balf, total mRNA was isolated and examined for transcript levels of the mitochondrial complex 1 markers (NDUFA1, NDUFA9, NDUFS7, ATP5F1) by RT-PCR analysis. Values represent the means ± SE of three independent experiments with 3 replicates per experiment. ^∗∗^*p* \< 0.01; ^∗∗∗^*p* \< 0.0001; ^∗∗∗∗^*p* \< 0.0001.
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Click here for additional data file.

###### 

Primer sequences of *NDUFA1*, *NDUFA9*, *NDUFS7*, *ATP5F1*.

###### 

Click here for additional data file.
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